Literature DB >> 28145912

Possible Opioid Shopping and its Correlates.

Alexander M Walker1, Lisa B Weatherby, M Soledad Cepeda, Daniel Bradford, Yingli Yuan.   

Abstract

BACKGROUND: We created an operational definition of possible opioid shopping in US commercial health insurance data and examined its correlates.
METHODS: The population consisted of 264,204 treatment courses in persons with a fill for an opioid or diuretic prescription in 2012 and a second within 18 months. We examined counts of prescribers and pharmacies and the numbers of fills and overlaps for ability to discriminate courses of opioids from diuretics, which were a negative control. The most discriminatory measure, indicating possible shopping behavior, was cross-tabulated against other prescriptions filled and diagnoses as found in insurance claims. The associations between claims characteristics and shopping behavior were assessed in a logistic regression.
RESULTS: A definition that classified possible "moderate" or "extensive" shopping when a person obtained drug through at least 3 practices and at least 3 pharmacies over 18 months was highly discriminatory between opioid and diuretic treatment. Overlaps between fills and number of fills did not improve the discrimination. Data from insurance claims strongly predicted moderate-to-extensive levels of possible shopping (c=0.82). Prominent among 20 significant predictors were: state of residence; amount of opioid dispensed; self-payment; use of nonspecialist prescribers; high use of anxiolytics, hypnotics, psychostimulants, and antipsychotics; and use of both immediate release and extended-release or long-acting opioids.
CONCLUSIONS: The use of ≥3 prescribing practices and ≥3 dispensing pharmacies over 18 months sharply discriminated courses of opioid treatment from courses of diuretics. This pattern of fills was additionally associated with the numbers of nonspecialist and self-paid fills, the total morphine milligram equivalents dispensed, and heavier use of drugs for anxiety, sleep, attention, and psychosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28145912     DOI: 10.1097/AJP.0000000000000483

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  6 in total

1.  Assessing treatment and monitoring of musculoskeletal conditions using opioid versus nonopioid therapy: A cross-sectional study.

Authors:  Derek P R Pierce; Brett Pierce; Chin-I Cheng; Juliette Perzhinsky
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

2.  Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data.

Authors:  Alexander M Walker; Lisa B Weatherby; M Soledad Cepeda; Daniel C Bradford
Journal:  Subst Abuse Rehabil       Date:  2019-08-01

3.  Medical record-based ascertainment of behaviors suggestive of opioid misuse, diversion, abuse, and/or addiction among individuals showing evidence of doctor/pharmacy shopping.

Authors:  Daina B Esposito; M Soledad Cepeda; Jennifer G Lyons; Ruihua Yin; Stephan Lanes
Journal:  J Pain Res       Date:  2019-07-24       Impact factor: 3.133

4.  Doctor hopping and doctor shopping for prescription opioids associated with increased odds of high-risk use.

Authors:  Sean G Young; Corey J Hayes; Jonathan Aram; Mark A Tait
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-06-05       Impact factor: 2.890

5.  The Association Between Doctor and Pharmacy Shopping and Self-Reported Misuse and Abuse of Prescription Opioids: A Survey Study.

Authors:  Judith J Stephenson; M Soledad Cepeda; Jie Zhang; Jade Dinh; Kelsey Hall; Daina B Esposito; David M Kern
Journal:  J Pain Res       Date:  2020-04-03       Impact factor: 3.133

6.  New means, new measures: assessing prescription drug-seeking indicators over 10 years of the opioid epidemic.

Authors:  Brea L Perry; Meltem Odabaş; Kai-Cheng Yang; Byungkyu Lee; Patrick Kaminski; Brian Aronson; Yong-Yeol Ahn; Carrie B Oser; Patricia R Freeman; Jeffrey C Talbert
Journal:  Addiction       Date:  2021-07-27       Impact factor: 6.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.